



ABN 53 075 582 740

ASX ANNOUNCEMENT
20 November 2020

AGM Results

Bionomics Limited (ASX:BNO, OTCQB: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all five resolutions considered before the Annual General Meeting today.

The Notice of Meeting and accompanying documents were lodged with ASX on 19 October 2020.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
Resolution 1. Adoption of Remuneration Report	Ordinary	54,407,727 83.51%	9,949,067 15.27%	791,843 1.21%	211,944,453	59,586,661 85.69%	9,949,067 14.31%	211,944,453	Carried
Resolution 2. Election of Non-Executive Director – Dr Srinivas Rao	Ordinary	274,369,406 98.85%	859,921 0.31%	2,307,607 0.84%	266,432	281,064,104 99.69%	859,921 0.31%	266,432	Carried
Resolution 3. Election of Non-Executive Director – Dr Jane Ryan	Ordinary	276,232,492 99.52%	375,559 0.14%	941,695 0.34%	253,620	281,561,278 99.87%	375,559 0.13%	253,620	Carried
Resolution 4. Approval of Bionomics Limited Employee Equity Plan	Ordinary	52,360,858 80.43%	11,830,703 18.17%	915,184 1.40%	212,329,923	57,658,733 82.97%	11,830,703 17.03%	212,334,323	Carried
Resolution 5. Approval of Proposed Issue of Share Options to Dr Jane Ryan	Ordinary	51,793,889 79.51%	12,433,422 19.09%	915,184 1.40%	212,294,173	57,091,764 82.12%	12,433,422 17.88%	212,298,573	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Mr Jack Moschakis

Legal Counsel & Company Secretary

+61 8 8354 6181

jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor.

Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au